CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04105374
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:37:46.610609+00:00
- Published At
- 2020-03-24T00:00:00+00:00
- Record Updated At
- 2020-03-24
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Anaplastic Astrocytoma", "Glioblastoma", "Oligodendroglioma", "Supratentorial Glioblastoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-03-24"- protocolSection.identificationModule.nctId
"NCT04105374"- protocolSection.identificationModule.officialTitle
"A Phase II/III Randomized, Open-Label Study of Toca 511, A Retroviral Replicating Vector, Combined With Toca FC With Temozolomide and Radiation Followed by Adjuvant Temozolomide and Toca FC Compared to Temozolomide and Radiation Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma"- protocolSection.statusModule.overallStatus
"WITHDRAWN"- protocolSection.designModule.phases
["PHASE2", "PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.